Retatrutide clinical trials by status
Most retatrutide trials are finished or fully enrolled. This is the count on ClinicalTrials.gov for studies with retatrutide (LY3437943) as an intervention, checked on November 13, 2026:[1]
| Status | Studies | What it means |
|---|---|---|
| Completed | 21 | Finished; some results published |
| Active, not recruiting | 9 | Running, closed to new participants |
| Recruiting | 2 | Open to new participants |
| Available (expanded access) | 1 | Single-patient access through a doctor |
Phase 3 trials
Phase 3 is the stage that supports an approval application. Lilly runs two programs: TRIUMPH (obesity and its complications) and TRANSCEND-T2D (type 2 diabetes). Enrollment below is the number registered on ClinicalTrials.gov, which can differ slightly from the number in the published paper.[1]
| Trial | Who | Enrolled | Status | Primary completion |
|---|---|---|---|---|
| TRIUMPH-1 (NCT05929066) | Obesity or overweight, no diabetes | 2,335 | Completed | April 2026 |
| TRIUMPH-2 (NCT05929079) | Obesity with type 2 diabetes | 1,152 | Completed | June 2026 |
| TRIUMPH-3 (NCT05882045) | Obesity with cardiovascular disease | 1,946 | Completed | April 2026 |
| TRIUMPH-4 (NCT05931367) | Obesity with knee osteoarthritis | 445 | Completed | November 2025 |
| TRIUMPH-5 (NCT06662383) | Obesity, vs tirzepatide | 800 | Active, not recruiting | November 2026 (estimated) |
| TRIUMPH-6 (NCT06859268) | Keeping weight off | 643 | Active, not recruiting | April 2028 |
| TRIUMPH-7 (NCT07035093) | Obesity with chronic low back pain | 586 | Active, not recruiting | September 2027 |
| TRIUMPH-8 (NCT07232719) | Obesity or overweight | 250 | Active, not recruiting | June 2027 |
| TRIUMPH-9 (NCT07357415) | Obesity, no diabetes | 600 | Active, not recruiting | October 2028 |
| TRIUMPH-Outcomes (NCT06383390) | Heart and kidney outcomes | 10,000 | Active, not recruiting | February 2029 |
| TRANSCEND-T2D-1 (NCT06354660) | Type 2 diabetes, diet and exercise only | 537 | Completed | January 2026 |
| TRANSCEND-T2D-2 (NCT06260722) | Type 2 diabetes, vs semaglutide | 1,250 | Active, not recruiting | August 2026 |
| TRANSCEND-T2D-3 (NCT06297603) | Type 2 diabetes with kidney impairment | 320 | Active, not recruiting | October 2026 |
| SYNERGY-Outcomes (NCT07165028) | Fatty liver disease (MASLD), several drugs | 4,500 | Recruiting | August 2030 |
Retatrutide trial results so far
Six phase 3 trials have reported results, in journals or in Lilly announcements. The headline weight figure for the 12 mg dose in each:
| Trial | First reported | Main result (12 mg) | Published in |
|---|---|---|---|
| TRIUMPH-4[5] | December 2025 | −23.7% weight at 68 weeks (all randomized) | NEJM, November 2026 |
| TRIUMPH-1[2] | May 2026 | −25.0% weight at 80 weeks (all randomized) | NEJM, September 2026 |
| TRANSCEND-T2D-1[7] | June 2026 | HbA1c −1.94 points, weight −15.3% at 40 weeks | The Lancet, June 2026 |
| TRIUMPH-2[3] | July 2026 | −18.8% weight at 80 weeks (all randomized) | The Lancet, September 2026 |
| TRIUMPH-3[4] | July 2026 | −22.6% weight at 80 weeks (Lilly figure) | Not yet in a journal |
| TRANSCEND-T2D-2[8] | October 2026 | −20.9% weight vs −9.4% on semaglutide at 80 weeks (Lilly figure) | Not yet in a journal |
Every dose, both counting methods and the placebo groups are on the retatrutide results page. The side effects reported in the same trials are on the side effects page.
Retatrutide in the NEJM and The Lancet
Retatrutide's main results have been published in the New England Journal of Medicine and The Lancet:
| Journal | Study | Published |
|---|---|---|
| NEJM[9] | Phase 2 obesity trial | June 2023 |
| The Lancet[10] | Phase 2 type 2 diabetes trial | June 2023 |
| The Lancet[7] | TRANSCEND-T2D-1 | June 2026 |
| NEJM[2] | TRIUMPH-1 | September 2026 |
| The Lancet[3] | TRIUMPH-2 | September 2026 |
| NEJM[6] | TRIUMPH-1-OSA and TRIUMPH-2-OSA (sleep apnea) | October 2026 |
| NEJM[5] | TRIUMPH-4 and TRIUMPH-1 knee substudy | November 2026 |
Phase 2 trials
| Trial | Who | Enrolled | Status |
|---|---|---|---|
| NCT04881760[9] | Obesity or overweight, 48 weeks | 338 | Completed; NEJM 2023; results posted |
| NCT04867785[10] | Type 2 diabetes, 36 weeks | 281 | Completed; The Lancet 2023; results posted |
| NCT05936151 | Obesity with chronic kidney disease, kidney function | 146 | Completed October 2025; results posted |
| NCT07467447 | Obesity or overweight, vs placebo (sites in China) | 300 | Recruiting; primary completion March 2027 |
Source: ClinicalTrials.gov records.[1]
Phase 1 studies
Fourteen phase 1 studies look at how the body handles the drug rather than at weight loss. Thirteen are completed and one, on insulin secretion and sensitivity in type 2 diabetes (NCT06982859), is due to finish in January 2027.[1] They include:
- The first single-injection safety study in healthy volunteers (NCT03841630, 2019) and early studies in type 2 diabetes in the U.S. and Japan.
- Studies in people with impaired kidney function (NCT05611957) and impaired liver function (NCT05916560).
- Drug-interaction studies, including one with the blood-pressure drug metoprolol (NCT06808802).
- A comparison of drug versions for different injection devices (NCT06003465), a study of calorie intake and energy use (NCT06313528), and a study of the body's response to low blood sugar (NCT06982846).
Recruiting retatrutide trials
Only two studies were open to new participants on November 13, 2026: SYNERGY-Outcomes, a liver-disease trial that tests several drugs in 34 countries including the United States, and a 300-person phase 2 obesity trial in China.[1] Outside trials, physicians can request single-patient expanded access.[11] Both routes are explained on how to get retatrutide.
What comes next
- TRIUMPH-5 (vs tirzepatide): main phase estimated to finish in November 2026. See retatrutide vs tirzepatide.
- TRANSCEND-T2D-3 (kidney impairment): main phase due October 2026, no results announced yet.
- TRIUMPH-8, TRIUMPH-7, TRIUMPH-6, TRIUMPH-9: 2027 to 2028.
- TRIUMPH-Outcomes: the 10,000-person heart and kidney trial, February 2029.
Dates are ClinicalTrials.gov estimates and often move.[1] The regulatory side is tracked on retatrutide FDA approval.
Frequently asked questions
How many retatrutide clinical trials are there?
ClinicalTrials.gov listed 33 studies on November 13, 2026, including 14 phase 3 trials (one of them a multi-drug liver-disease trial) and an expanded-access program.[1]
Are any retatrutide trials recruiting?
Two were: SYNERGY-Outcomes (fatty liver disease, 34 countries including the U.S.) and a phase 2 obesity trial in China.[1]
Where are retatrutide trial results published?
When will the TRIUMPH-5 results come out?
Its main phase is estimated to finish in November 2026. Lilly has not announced a date for results.[1]
Sources
- Retatrutide studies (NCT04881760, NCT05929066, NCT05931367, NCT06662383, NCT07629401 and others)
- Jastreboff AM et al. Retatrutide for obesity (TRIUMPH-1)
- Bellido V et al. Retatrutide in obesity with type 2 diabetes (TRIUMPH-2)
- Lilly: retatrutide successful in two additional phase 3 obesity trials (TRIUMPH-2, TRIUMPH-3)
- Schnitzer TJ et al. Retatrutide in obesity and knee osteoarthritis (TRIUMPH-4)
- Grunstein RR et al. Retatrutide for obstructive sleep apnea (TRIUMPH-1-OSA, TRIUMPH-2-OSA)
- Bajaj HS et al. Retatrutide in type 2 diabetes (TRANSCEND-T2D-1)
- Lilly: retatrutide vs semaglutide 2 mg in TRANSCEND-T2D-2
- Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial
- Rosenstock J et al. Retatrutide in people with type 2 diabetes: a phase 2 trial
- Pre-approval expanded access of retatrutide (LY3437943), NCT07629401